Portfolio company
Human Immunology Biosciences (HI-Bio)
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This biotechnology company develops targeted immunotherapies for patients with rare, severe immune-mediated diseases, such as chronic kidney conditions and antibody-mediated transplant rejection.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
HI-Bio
This biotechnology company develops targeted therapies for patients suffering from severe immune-mediated diseases.
Clim Bio
This biotechnology company develops antibody-based medicines for patients with immune-mediated diseases such as lupus and IgA nephropathy.
Jasper Therapeutics
This company develops antibody therapies for patients with immune-mediated diseases, including renal disorders, mast cell conditions and paroxysmal nocturnal haemoglobinuria.
Hummingbird Bioscience
This company develops antibody-based therapeutics and drug conjugates for patients with hard-to-treat cancers and autoimmune diseases.
Thymmune
This biotechnology company develops scalable thymic cell therapies to restore immune function for patients with immunodeficiencies, autoimmune disorders, and transplant-related conditions.
Ouro Medicines
This biotechnology firm develops T-cell engager therapies to treat patients living with chronic immune-mediated diseases.
Hillstar Bio
This biotechnology company develops precision immunology therapies that target and deplete pathogenic immune cells for patients with autoimmune diseases.
Evommune
This biotechnology company develops medicinal therapies to treat patients suffering from chronic inflammatory and immune-mediated diseases.
